On April 24, Jiuzhoutong released its 2016 annual report. The report shows that in 2016, Jiuzhoutong achieved operating income of 61.557 billion yuan, operating profit of 1.049 billion yuan and net profit of 904 million yuan (including attributable to listed companies). Net profit of shareholders was 877 million yuan, compared with operating income of 49.589 billion yuan, operating profit of 860 million yuan and net profit of 704 million yuan (including net profit of 6.95 shareholders of listed companies). 100 million yuan) increased by 24.13% and 22.00% respectively.

Western medicine, Chinese patent medicine sales contributed the most

Founded in 1985, Kyushutong has started from the pharmaceutical retail business and has now extended to all aspects of the pharmaceutical circulation field. According to the annual report, in 2016, Kyushutong mainly focused on four major businesses, including wholesale products for pharmaceuticals, medical devices, retail chain operations, pharmaceutical production and R&D, and logistics management.

Among them, in the wholesale business of pharmaceuticals, medical devices and other products, the main types of drugs, medical devices and other varieties are close to 250,000, including Fufang Danshen Dripping Pills, Xingai Zhonggai High Calcium Tablets, and Sanjing Gold Zinc Oxate Oral Liquid. , Ejiao, Cordyceps sinensis and other pharmaceutical market explosions.

In terms of retail chain business, Kyushutong has been engaged in pharmaceutical retail chain operation since 2003, using its existing distribution capabilities, marketing network and variety resources to start and develop retail chain businesses in well-established provinces, municipalities and autonomous regions. The online e-commerce platform of large pharmacies and good pharmacists has formed an integrated service. As of December 31, 2016, Jiuzhoutong had 911 chain drug stores across the country.

In addition to pharmaceutical agents and retail sales, Kyushutong has also achieved good results in pharmaceutical production and R&D. As of the end of December 2016, Jiuzhoutong and its subsidiaries have obtained 88 national drug approval numbers, and the main production varieties include Cefaclor dispersible tablets, cefradine capsules, cephalexin tablets, azithromycin dispersible tablets, levofloxacin hydrochloride tablets, levofloxacin hydrochloride capsules, acetylspiramycin tablets, norfloxacin capsules, and the like.

At the same time, Kyushutong is also actively deploying the layout of important industries. Kyushutong's subsidiary Kyushu Tianrun Chinese Medicine Industry Co., Ltd. is a Chinese medicine business platform. The subsidiary has a Chinese medicine research institute and six Chinese medicine production standards that have passed the national GMP certification. Subsidiary, at present, the company owns two major private brands, namely “Jingui Dejitang” and “Ziyang”, and has applied for and obtained registered trademarks such as “Huiyang” and “Jingui Dejitang”, which have been developed including American ginseng and Sanqi powder. And other products.

Triangular Bandage

Triangular Bandage, Cotton Triangular Bandage, Non-woven Triangular Bandage, Non woven Triangular Bandage, Sterile Triangular Bandage, Medical Triangular Bandage

Triangular Bandage,Cotton Triangular Bandage,Non-woven Triangular Bandage,Non woven Triangular Bandage,Sterile Triangular Bandage

Luck Medical Consumables Co.,LIMITED , https://www.luckmedical.com